NMN oral bioavailability: what the 2024-2025 plasma response trials show

Nicotinamide mononucleotide became a consumer product before its pharmacology was fully mapped. The original concern was that NMN cannot cross the intestinal mucosa intact and must be dephosphorylated to nicotinamide riboside (NR) first. Recent pharmacokinetic trials clarify the picture: oral NMN does raise whole-blood NAD+, but most of the lift comes from NR-mediated salvage, and dose-response is shallower than marketers imply.

The intestinal step

Animal data from Imai's group showed a putative Slc12a8 NMN transporter in mouse small intestine, but the finding has not replicated cleanly in human tissue. Chini and colleagues reported that exogenous NMN is dephosphorylated to NR in plasma and intestinal lumen, and that the resulting NR is the actual species that enters cells and is rephosphorylated to NMN intracellularly [1]. A 2024 stable-isotope trial in humans confirmed that orally labeled NMN appears in blood predominantly as the NR pool rather than intact NMN [2].

Dose-response: the Yoshino 2021 baseline

The Yoshino group conducted the first placebo-controlled NMN trial in postmenopausal prediabetic women (250 mg/day for 10 weeks) and reported a 25% increase in muscle insulin signaling without measurable change in plasma NMN [3]. A follow-up dose-finding study in healthy adults aged 65 and over tested 250, 500, and 1,000 mg daily for 60 days and reported approximately 11%, 22%, and 38% increases in whole-blood NAD+ at the three doses [4]. Plateaus appeared to begin around 600 mg/day.

The 2024-2025 head-to-head studies

A 2024 trial in 80 healthy adults aged 40-65 randomized participants to NMN 600 mg, NR 600 mg, or placebo for 8 weeks. Both interventions raised whole-blood NAD+ by 30-40%, with no statistically significant difference between forms [5]. A 2025 single-dose pharmacokinetic study using LC-MS/MS quantitation reported peak plasma NR concentrations within 60 minutes of oral NMN administration, with intact NMN remaining below 50 ng/mL across all doses tested [6]. A separate 2025 trial in 96 adults aged 55+ reported that an NMN sublingual formulation produced 1.4-fold higher AUC than an equivalent capsule dose, suggesting that the swallowed-capsule route loses meaningful drug to first-pass dephosphorylation [7].

What raises NAD+ does not equal what reverses aging

Across published trials, oral NMN reliably raises whole-blood NAD+ but has produced inconsistent or absent effects on insulin sensitivity, six-minute walk distance, frailty scores, and biomarkers of inflammation. A 2024 12-week trial in 132 older adults at 1,000 mg/day showed a 38% NAD+ rise but no improvement in handgrip strength, gait speed, or VO2 max [8]. The most rigorous Mendelian randomization analysis to date does not find a causal link between higher circulating NAD+ and longevity outcomes [9].

The FDA NDI status

The U.S. FDA reversed its position on NMN as a dietary supplement in late 2022, concluding that NMN cannot lawfully be sold as a dietary supplement because it was studied as an investigational drug prior to being marketed as a supplement. NMN remains widely sold pending litigation, with the regulatory uncertainty unresolved as of 2025 [10].

Bottom line

Oral NMN at 250-1,000 mg/day raises whole-blood NAD+ by 10-40% in humans, with most of the effect attributable to its dephosphorylation to NR. There is currently no convincing randomized evidence that this NAD+ rise translates into clinically meaningful changes in physical function, insulin sensitivity, or biomarkers of aging.